文献速递鼻科

下鼻甲注射A型肉毒毒素治疗慢性鼻炎

Turbinate Injection of Botulinum Toxin in the Treatment of the Chronic Rhinitis.
PubMed 文献 · Laryngoscope · 2024-12-03

本系统综述与Meta分析纳入7项研究共269例患者,评估鼻内A型肉毒毒素(BTX-A)下鼻甲注射对慢性鼻炎相关症状的影响。BTX-A注射后鼻塞、鼻痒、流涕、打喷嚏、鼻部症状总分及生活质量均改善,但3个月时症状改善未达统计学显著,效应仅持续约2-3个月。

要点

  • BTX-A下鼻甲注射后鼻塞、鼻痒、流涕、打喷嚏及生活质量评分均下降。
  • 注射3个月后症状改善虽仍存在,但未达统计学显著。
  • 过敏性鼻炎患者的症状改善优于非过敏性鼻炎患者。

核心结论

  • BTX-A注射后鼻炎相关鼻部症状与生活质量评分下降,对过敏性鼻炎疗效更好,对鼻塞和流涕在治疗早期更有益。
  • 疗效持续时间相对较短,仅2-3个月。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、SCOPUS、Embase、Web of Science和Cochrane数据库截至2024年8月的研究。
  • 分析评估BTX-A注射前后鼻炎相关症状评分与生活质量变化幅度的研究,共纳入7项研究269例患者,采用标准均数差计算效应量。

主要发现

  • 鼻塞标准均数差2.5416(95%CI 1.0927-3.9905,I²=94.4%),鼻痒1.2553(95%CI 0.6660-1.8446,I²=70.8%)。
  • 流涕1.8451(95%CI 1.0468-2.6435,I²=89.7%),打喷嚏1.3580(95%CI 0.5194-2.1967,I²=90.7%)。
  • 鼻部症状总分2.4020(95%CI 1.4161-3.3879,I²=86.1%),生活质量1.5256(95%CI 1.0760-1.9752,I²=0.0%),随访期4个月。
  • 注射3个月后症状改善仍存在,但未达统计学显著。
  • 过敏性鼻炎患者较非过敏性鼻炎患者鼻炎相关症状改善显著。

关键数值与推荐

  • 鼻塞标准均数差2.5416(95%CI 1.0927-3.9905,I²=94.4%)。
  • 鼻痒标准均数差1.2553(95%CI 0.6660-1.8446,I²=70.8%)。
  • 流涕标准均数差1.8451(95%CI 1.0468-2.6435,I²=89.7%)。
  • 打喷嚏标准均数差1.3580(95%CI 0.5194-2.1967,I²=90.7%)。
  • 鼻部症状总分标准均数差2.4020(95%CI 1.4161-3.3879,I²=86.1%),生活质量1.5256(95%CI 1.0760-1.9752,I²=0.0%)。

临床怎么用

  • 作者认为BTX-A下鼻甲注射可降低鼻炎相关鼻部症状与生活质量评分,在过敏性鼻炎中疗效更好,对鼻塞和流涕在治疗早期更有益。
  • 作者指出疗效仅持续2-3个月,相对较短。

局限性

  • 原文报告各症状合并分析的异质性较高:鼻塞I²=94.4%、鼻痒I²=70.8%、流涕I²=89.7%、打喷嚏I²=90.7%、鼻部症状总分I²=86.1%。
  • 原文报告BTX-A注射3个月后症状改善未达统计学显著。
  • 原文报告疗效持续时间相对较短,仅2-3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This systemic review with meta-analysis evaluated the effect of intranasal BTX-A turbinate injection on chronic rhinitis-related symptoms. DATA SOURCES: PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases. REVIEW METHODS: We reviewed studies retrieved from databases up to Aug 2024. The studies evaluating the degree of change of rhinitis-related symptom scores and quality of life before and after BTX-A injection were analyzed. Standard mean differences were used to calculate effect sizes. RESULTS: A total of 269 patients from 7 studies were analyzed. BTX-A injection showed a significant improvement in rhinitis-related symptoms (congestion: 2.5416, 95% CI 1.0927-3.9905, I2 = 94.4%, itching: 1.2553, 95% CI 0.6660-1.8446; I2 = 70.8%, rhinorrhea: 1.8451, 95% CI 1.0468-2.6435, I2 = 89.7%, and sneezing: 1.3580, 95% CI 0.5194-2.1967; I2 = 90.7%), total nasal symptom score (2.4020, 95% CI 1.4161-3.3879, I2 = 86.1%), and quality of life (1.5256, 95% CI 1.0760-1.9752; I2 = 0.0%) throughout the follow-up period (4 months). However, 3 months after injection, although symptom improvement remained, there was no statistical significance. Allergic rhinitis (AR) patients showed a significant improvement in rhinitis-related symptoms compared with nonallergic rhinitis (NAR) patients. CONCLUSIONS: Nasal symptoms and quality of life scores related to rhinitis were decreased after BTX-A injection. In particular, this treatment showed better efficacy in AR and could be more beneficial for the symptoms of nasal congestion and rhinorrhea at the early periods of treatment. However, the effects lasted for a relatively short period of only 2-3 months. Laryngoscope, 135:1545-1552, 2025.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Kim DH, Jang DW, Hwang SH, et al. Turbinate Injection of Botulinum Toxin in the Treatment of the Chronic Rhinitis. Laryngoscope. 2024. PMID: 39625109. doi:10.1002/lary.31936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。